OBJECTIVE: To evaluate pretherapy ribonucleotide reductase (RNR) expression and its effect on radiochemotherapeutic outcome in women with cervical cancer. METHODS/MATERIALS: Pretherapy RNR M1, M2, and M2b immunohistochemistry was done on cervical cancer specimens retrieved from women treated on Radiation Therapy Oncology Group (RTOG) 0116 and 0128 clinical trials. Enrollees of RTOG 0116 (node-positive stages IA-IVA) received weekly cisplatin (40 mg/m(2)) with amifostine (500 mg) and extended-field radiation then brachytherapy (85 Gy). Enrollees of RTOG 0128 (node-positive or bulky ≥5 cm, stages IB-IIA or stages IIB-IVA) received cisplatin (75 mg/m(2)) on days 1, 23, and 43 and 5-FU (1 g/m(2) for 4 days) during pelvic radiation then brachytherapy (85 Gy), plus celecoxib (400 mg twice daily, day 1 through 1 year). Disease-free survival (DFS) was estimated univariately by the Kaplan-Meier method. Cox proportional hazards models evaluated the impact of RNR immunoreactivity on DFS. RESULTS: Fifty-one tissue samples were analyzed: 13 from RTOG 0116 and 38 from RTOG 0128. M1, M2, and M2b overexpression (3+) frequencies were 2%, 80%, and 47%, respectively. Low-level (0-1+, n = 44/51) expression of the regulatory subunit M1 did not associate with DFS (P = 0.38). High (3+) M2 expression occurred in most (n = 41/51) but without impact alone on DFS (hazard ratio, 0.54; 95% confidence interval, 0.2-1.4; P = 0.20). After adjusting for M2b status, pelvic node-positive women had increased hazard for relapse or death (hazard ratio, 5.5; 95% confidence interval, 2.2-13.8; P = 0.0003). CONCLUSIONS: These results suggest that RNR subunit expression may discriminate cervical cancer phenotype and radiochemotherapy outcome. Future RNR biomarker studies are warranted.
OBJECTIVE: To evaluate pretherapy ribonucleotide reductase (RNR) expression and its effect on radiochemotherapeutic outcome in women with cervical cancer. METHODS/MATERIALS: Pretherapy RNR M1, M2, and M2b immunohistochemistry was done on cervical cancer specimens retrieved from women treated on Radiation Therapy Oncology Group (RTOG) 0116 and 0128 clinical trials. Enrollees of RTOG 0116 (node-positive stages IA-IVA) received weekly cisplatin (40 mg/m(2)) with amifostine (500 mg) and extended-field radiation then brachytherapy (85 Gy). Enrollees of RTOG 0128 (node-positive or bulky ≥5 cm, stages IB-IIA or stages IIB-IVA) received cisplatin (75 mg/m(2)) on days 1, 23, and 43 and 5-FU (1 g/m(2) for 4 days) during pelvic radiation then brachytherapy (85 Gy), plus celecoxib (400 mg twice daily, day 1 through 1 year). Disease-free survival (DFS) was estimated univariately by the Kaplan-Meier method. Cox proportional hazards models evaluated the impact of RNR immunoreactivity on DFS. RESULTS: Fifty-one tissue samples were analyzed: 13 from RTOG 0116 and 38 from RTOG 0128. M1, M2, and M2b overexpression (3+) frequencies were 2%, 80%, and 47%, respectively. Low-level (0-1+, n = 44/51) expression of the regulatory subunit M1 did not associate with DFS (P = 0.38). High (3+) M2 expression occurred in most (n = 41/51) but without impact alone on DFS (hazard ratio, 0.54; 95% confidence interval, 0.2-1.4; P = 0.20). After adjusting for M2b status, pelvic node-positive women had increased hazard for relapse or death (hazard ratio, 5.5; 95% confidence interval, 2.2-13.8; P = 0.0003). CONCLUSIONS: These results suggest that RNR subunit expression may discriminate cervical cancer phenotype and radiochemotherapy outcome. Future RNR biomarker studies are warranted.
Authors: Peter G Rose; Shamshad Ali; Charles W Whitney; Rachelle Lanciano; Frederick B Stehman Journal: Gynecol Oncol Date: 2011-03-21 Impact factor: 5.482
Authors: Charles A Kunos; Tomas Radivoyevitch; John Pink; Song-Mao Chiu; Tammy Stefan; James Jacobberger; Timothy J Kinsella Journal: Radiat Res Date: 2010-09-10 Impact factor: 2.841
Authors: Charles A Kunos; Valdir C Colussi; John Pink; Tomas Radivoyevitch; Nancy L Oleinick Journal: Int J Radiat Oncol Biol Phys Date: 2011-04-04 Impact factor: 7.038
Authors: Patricia J Eifel; Kathryn Winter; Mitchell Morris; Charles Levenback; Perry W Grigsby; Jay Cooper; Marvin Rotman; David Gershenson; David G Mutch Journal: J Clin Oncol Date: 2004-03-01 Impact factor: 44.544
Authors: Joanne B Weidhaas; Shu-Xia Li; Kathryn Winter; Janice Ryu; Anuja Jhingran; Bridgette Miller; Adam P Dicker; David Gaffney Journal: Clin Cancer Res Date: 2009-06-09 Impact factor: 12.531
Authors: Giovanna Pontarin; Artur Fijolek; Paola Pizzo; Paola Ferraro; Chiara Rampazzo; Tullio Pozzan; Lars Thelander; Peter A Reichard; Vera Bianchi Journal: Proc Natl Acad Sci U S A Date: 2008-11-07 Impact factor: 11.205
Authors: Charles Kunos; Wei Deng; Dawn Dawson; Jayanthi S Lea; Kristine M Zanotti; Heidi J Gray; David P Bender; Perry P Guaglianone; Jori S Carter; Kathleen N Moore Journal: Int J Gynecol Cancer Date: 2015-03 Impact factor: 3.437
Authors: David K Gaffney; Anuja Jhingran; Lorraine Portelance; Akila Viswanathan; Tracey Schefter; Joanne Weidhaas; William Small Journal: Int J Gynecol Cancer Date: 2014-06 Impact factor: 3.437
Authors: Charles A Kunos; Edward Chu; Della Makower; Andreas Kaubisch; Mario Sznol; Susan Percy Ivy Journal: Front Oncol Date: 2017-04-04 Impact factor: 6.244